SAFETY
NEMLUVIO offers a favorable safety profile1
TREATMENT-EMERGENT ADVERSE REACTIONS1
Occurring in ≥1% of the NEMLUVIO group and greater than placebo*
ADVERSE REACTION | NEMLUVIO | PLACEBO |
---|---|---|
Atopic dermatitis | 4% | 0.5% |
Eczema | 4% | 2% |
Headache† | 6% | 3% |
Nummular eczema | 3% | 0 |
NEMLUVIO was well tolerated in the OLYMPIA long-term extension (LTE) study, with long-term safety data consistent with the previously reported safety of the OLYMPIA Phase 3 pivotal trials.2
In the OLYMPIA 1 and OLYMPIA 2 trials through treatment period.
Includes headache and tension headache.1
No increased incidence compared to placebo3:
No lab tests with
NEMLUVIO1:
Fast Itch Relief2
See how NEMLUVIO significantly improved itch in both pivotal and long-term studies2
Q4W Dosing From the Start1
NEMLUVIO offers the convenience of less frequent dosing compared to the other biologic for PN1,4
Sign up now for more information about NEMLUVIO and PN
PN=prurigo nodularis; Q4W=every 4 weeks.
References: 1. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P.; August 2024. 2. Galderma Laboratories, L.P.; data on file. 3. Galderma Laboratories, L.P.; data on file. Clinical Study Report RD.06.SRE.203065; September 2023. 4. DUPIXENT. Prescribing information. Sanofi Genzyme; 2024.